43
Participants
Start Date
February 28, 2006
Primary Completion Date
April 30, 2011
Study Completion Date
August 31, 2012
suberoylanilide hydroxamic acid (SAHA, Vorinostat)
Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance. All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks. Responses will be assessed after 2 cycles (8 weeks + 4 days).
tamoxifen citrate (Tamoxifen)
Tamoxifen will be given once daily at 20 mg. Tamoxifen will be given continuously. Responses will be assessed after 2 cycles (8 weeks + 4 days).
St. Joseph's/Candler, Savannah
Tallahassee Memorial HealthCare, Inc., Tallahassee
M.D. Anderson of Orlando, Orlando
Bethesda Memorial Hospital Research Center, Boynton Beach
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Fawcett Memorial Hospital, Port Charlotte
Martin Memorial Cancer Center, Stuart
University of California, San Francisco
Merck Sharp & Dohme LLC
INDUSTRY
H. Lee Moffitt Cancer Center and Research Institute
OTHER